Artificial Intelligence (AI) in Healthcare Accounting

Artificial Intelligence (AI) in Healthcare Accounting: Financial Implications of AI

Applications in Medical Diagnosis and Treatment

Introduction

Artificial intelligence is rapidly transforming the healthcare industry through new technologies

that assist or augment human diagnostic, treatment and care decisions. AI tools are being

applied across a wide array of domains from medical imaging analysis and precision

oncology to telehealth services, pharmaceutical research and beyond. While offering

immense potential to improve patient outcomes and access to care, widespread adoption of

AI also carries financial implications for organizations. This paper examines the accounting

and budget implications of AI adoption within healthcare, exploring both costs and potential

cost savings associated with AI applications in clinical diagnosis and treatment. It will

analyze how healthcare organizations can strategically plan for and measure the return on

investment of AI technologies from an accounting perspective to maximize benefits while

controlling expenditures.

Background on AI in Healthcare

AI refers broadly to computer systems able to perform tasks typically requiring human

intelligence by using machine learning algorithms and large data sets. Within healthcare,

some common applications of AI currently include:

- Medical imaging analysis using deep learning on scans like x-rays, CTs, MRIs to detect

abnormalities, segment lesions for volumetric measurements or guide biopsy procedures.

Some estimates suggest AI can analyze medical images 6 times faster than humans.

- Precision medicine through analysis of huge genetic, clinical and molecular datasets to

derive insights on individualized risk, screening, treatment selection. Can reveal patterns not

obvious to clinicians.

- Administrative automation through natural language processing of medical records,

insurance claims to extract structured data fields for coding, billing functions at scale

surpassing manual review.

- Virtual assistants powered by AI and leveraging real-time data to provide patients

condition-specific guidance on symptoms, risks, self-care via web, voice, mobile interfaces.

Augmenting usual patient education resources.

- AI-guided surgical robots offering precise, minimally invasive procedures through computer

vision, motion sensors, multi-articulated instruments controlled wirelessly by surgeons.

Claims of 98% success rates on some procedures.

- Drug discovery through AI screening of millions of molecular compounds to predict

interactions, side effects profiles not feasible via traditional experimentation alone. Can

expedite new therapies.

While clinical benefits of these AI tools are promising such as reduced diagnostic errors,

more personalized care plans and expanded access in underserved areas, each new

technology also introduces budget factors that healthcare organizations will need to manage

strategically.

AI Adoption Costs and Investment Requirements

Deploying and fully utilizing advanced AI capabilities within medical settings entails certain

non-trivial upfront and ongoing costs that organizations must budget for:

- Hardware/infrastructure - High performance compute clusters, large scale data storage,

high bandwidth networking required to power complex deep learning models is capital

intensive initially, plus annual maintenance.

- AI platform/software - Licensing fees, subscription costs for proprietary AI platforms,

toolkits. Custom solution development contracting isn't cheap either.

- Data onboarding - Initial costs of digitizing paper records, structuring unstructured data,

addressing inconsistencies, integrating disparate sources are substantial non-recurring

investments that enable the “train” phase of AI.

- IT implementation support - Additional clinical informaticists, data scientists and engineers

to on-board new technologies, address interface challenges, integrate with EHRs, support

clinicians as they adopt. Ongoing skillset.

- Physician training - Time spent educating physicians, nurses on using new AI-powered

clinical support tools, interpreting results, incorporating AI guidance into workflows needs to

be accounted for.

- Vendor/consulting services - Implementation partners with AI expertise are necessary for

many healthcare organizations just starting their AI journeys due to skills gaps. Their

services come at a cost.

- Regulation/compliance - Additional processes, documentation, security controls required as

medical AI tools themselves become regulated medical devices. Increased oversight incurs

budget implications.

- Ongoing model training - Continued financing required to keep AI models trained on

expanding clinical datasets, testing against additional use cases, re-training as best

practices evolve over time. Not a one-time investment.

Proper accounting for these AI adoption capital and operating expenditures in long range

strategic plans is essential for organizations to budget effectively to support new

technologies as they come online over the next 5-10 years. ROI expectations must be

realistic based on true total costs of ownership.

Cost Savings and Efficiency Gains from AI

While direct adoption costs exist, when applied appropriately AI tools also promise

significant efficiencies and cost reductions that can offset investment requirements if

measured and managed properly:

- Reduced diagnostic errors - AI tools assisting in medical imaging analysis, precision

oncology decision support and other clinical domains can reduce the costs of missed,

delayed or improper diagnoses over time through improved outcomes.

- Decreased physician workload - AI taking over administrative tasks like note transcription,

coding/billing data extraction as well as basic diagnostic functions like reviewing certain

imaging exams frees clinicians to focus higher value work. Reduced burnout improves

retention too.

- Streamlined referral management - AI guiding evidence-based specialty referrals based on

individual patient profiles can reduce unnecessary consults or follow ups that do not change

management, sparing cost of extra testing, visits and procedures.

- Increased remote patient monitoring - AI/ML analytics of patient physiologic and symptom

datasets captured outside clinical settings enable early detection of health status changes

without requiring costly office or ER visits until truly necessary.

- Faster clinical trials - AI accelerating drug discovery, enrollment matching, endpoint

analysis in trials stands to significantly shorten development cycles and bring new therapies

to market faster at lower per-patient research costs.

- Reduced readmissions - Precise predictive analytics of individual 30-90 day readmission

risks power more targeted transitional care interventions proven to lower readmit rates and

associated penalties or losses.

- Improved population health management - Aggregate insights on high-risk, high-cost

patient cohorts gleaned from gigantic clinical-social determinants datasets when overlaid

with ML-guided outreach can lower overall per capita healthcare spending in a community.

Properly tracking, measuring and attributing cost reductions and avoided expenses enables

justifying AI investment requirements through hard ROI calculations.

Accounting for ROI of AI Technologies

For healthcare organizations to reap the full budgetary benefits of AI while managing costs,

having a defined process to account for and measure ROI is important. Key considerations

include:

- Prospectively estimating costs savings by use case based on pilot program data or

published studies factoring in organization’s specific context, cost structures and

performance baselines. Establish benchmarks and target savings.

- Tracking actual costs to implement and operationalize each AI application, including direct

purchase/license costs plus indirect implementation support, change management

overhead. Monitor variances.

- Developing expense tracking categories in accounting systems specifically to attribute

costs and savings by AI program for ease of measurement and long-term sustainability of

ROI reporting. Avoid generic cost pools.

- Surveying clinicians to assess time savings realized, efforts redeployed to higher value

activities plus impacts to outcomes, readmissions and other key success metrics. Convert to

cost benefits.

- Analyzing claims, charge and other transactional datasets with analytical tools to

statistically validate reduction in spend, denials or unnecessary utilization associated with

targeted AI applications.

- Considering indirect intangible ROI like improved brand reputation from early AI adoption

driving expanded market share or demand that contributes to top-line through new patient

volumes funneled to organizations over competitors.

- Projecting multiperiod ROI timelines for AI investments not yielding positive returns for 3-5

years allowing for amortization of infrastructure development portions of initial capital

outlays. Dynamic ROI targets.

- Regularly reporting ROI measures achieved against targets to executive teams for ongoing

AI prioritization, refinement decisions and securing continued investment support across

leadership teams.

By establishing formal ROI measurement processes, healthcare organizations obtain the

data rigor to justify expanding strategic AI deployments sustainably in ways purely clinical

benefits alone may not accommodate financially.

Budget Modeling Approaches

Armed with cost and ROI baselines from pilots and early adopters, healthcare CFOs and

financial planners can develop multi-year budgetary projections and modeling scenarios

around scaling organization-wide AI initiatives that balance expected returns with controlled

annual spending commitments:

- Rolling 5-year capital and operating expense budgets incorporating annual increases to

fund expanding AI deployments across imaging analysis, precision oncology, chronic

disease management, population health programs etc.

- Sensitivity analysis adjusting projected cost savings and timeline achievement based on

potential variables to size the scale/scope of AI programs affordably without undue

budgetary risks upfront.

- Scenario modeling establishing ROI-based funding triggers to automatically greenlight the

next phase of deployments once financial targets are met on current initiatives, sustaining

ROI-driven expansions.

- Strategic sourcing to negotiate AI vendor/consulting contracts leveraging total multi-year

spending commitments at optimized pricing supporting affordable multi-year rollouts.

- Justifying pay-for-performance contracting arrangements with AI vendors based on

validated achievement of ROI targets established through multi-period budgetary analysis

and projections.

- Multi-source funding models incorporating capital from systems integration optimization

projects, service line growth opportunities, strategic partnerships/joint ventures in addition to

traditional capital budgets.

- Dynamic budget reforecasting as pilots yield earlier-than-expected reductions enabling

pulling investment timelines left without compromising fiscal stewardship or profitability

goals.

By establishing a thorough yet flexible long range AI financial plan and budgeting framework,

healthcare leaders position their organizations to scale transformative technologies

responsibly within available fiscal capacity driven by measurable ROI achievement.

Regulatory Financial Reporting Considerations

As AI-powered clinical decision support tools and applications take on more autonomous

diagnostic and therapeutic functions over time, financial accounting standards and regulatory

agencies will evolve requirements around medical AI commercialization, reimbursement and

cost reporting as well. Some emerging issues include:

- Classifying AI-related capital and operating costs for rate-setting and program integrity

monitoring by payers. Proper cost segregation essential to avoid disputes.

- Monitoring and reconciling utilization, outcomes and spending shifts attributable to new

forms of guideline-driven or autonomous care enabled by AI tools for regulatory filings,

population health assessments.

- Tracking AI model performance quality and ongoing improvement metrics to demonstrate

clinical validity, usefulness for certification/clearance renewal or coverage/payment decisions

from agencies.

- Accounting for capital invested in FDA/CMS approved clinical AI tools distinct from general

IT assets for tax, depreciation and return-on-capital employed purposes when devices

commercialized.

- Applying grants accounting practices to public-private partnerships funding non-commercial

AI discovery work or pilot programs involving research organizations, payers, manufacturers.

- Preparing to report AI tool usage, clinician oversight and other metrics as regulatory focus

elevates on algorithmic transparency, model explainability, third-party oversight of advanced

medical AI systems.

- Adapting financial systems and consolidation procedures to capture costs, revenues

flowing between integrated delivery networks, academic medical centers, multinational

manufacturers/ AI firms pursuing novel joint ventures in digital health.

While still emerging, these regulatory financial considerations highlight the planning required

now to smoothly adapt accounting practices as healthcare AI matures and accountability

expectations from oversight bodies evolve concurrently over the coming decade.

Managing Budget Uncertainty

Until medical AI adoption scales significantly, significant uncertainties remain around true

costs, savings distributions and timing of returns that prudent fiscal stewardship demands

healthcare leaders budget, account and mitigate carefully through reserves and

contingencies:

- AI investments carrying long ROI periods may underperform initial projections necessitating

larger reserve allocations in early years to avoid destabilizing core operations.

- Not all targeted use cases may pan out as envisioned through pilots requiring ability to

redirect slack resources to those gaining traction faster. Flexible annual plans.

- Interoperability, interface challenges integrating AI within clinical workflows could drive

deployment timelines and support costs higher initially until stabilize. SAFE buffers.

- Regulatory paradigm changes on the horizon may spur unpredictable mandatory

investments in model validation infrastructure, security controls or interface standards that

require dedicated contingency funding ahead of rulemakings.

- Shortages in data science/clinical informatics talent could inflate AI project labor costs

unpredictably compared to nominal budgeting if not mitigated through partnerships.

- Budgeted cost-offsets and ROI may scale more gradually than planned if behavioral

adoption curves of new technologies rise slower than assumed in financial projections.

Gradual benchmarks, no cliffs.

Accounting practices that incorporate adequate funding reserves, ROI risk adjustment

factors and scenario-based contingencies during AI's early-stage adoption period are

financially prudent and support sustained large-scale technology deployments through

normal uncertainties.

Conclusion

While presenting unprecedented potential to transform healthcare delivery, AI technologies

also introduce new organizational budgeting complexities to account for strategically. By

establishing rigorous processes to measure and justify adoption costs as well as validate

hard cost-savings, efficiencies and ROI over multiple fiscal periods, healthcare executives

can scale AI initiatives responsibly within available fiscal means. From pilots to scaled

rollouts, prudent accounting of medical AI's financial realities sustains these transformational

technologies as vibrant long-term priorities alongside tradition foci on clinical outcomes and

quality of care metrics alone. With accurate ROI targeting, pragmatic expense management

through uncertainties and adherence to regulatory financial oversight, healthcare

organizations position themselves best to realize AI's promise sustainably for years to come.